CEOCFO: Mr. Sharma, what is the main thrust for Celprogen today?
Mr. Sharma: Celprogen remains focused on developing novel non-toxic drugs against cancers of the pancreas, colon, lung, skin and brain.

CEOCFO: Why those particular areas?
Mr. Sharma: Cancers in these target organs are challenging based on current treatment paradigms and can benefit from Celprogen’s novel drugs aimed to improve the life expectancy of patients who currently succumb to their disease.

CEOCFO: What is your approach?
Mr. Sharma: Celprogen’s drugs target cancer stem cells, a subset of cells with immense regenerative capacity and resistant to chemo and radiation therapy. These cancer stem cells lead to tumor recurrence and are detrimental to the patient’s life.

CEOCFO: Would you give us an idea of science behind your therapy? What are you doing to see if this approach works?
Mr. Sharma: Using a variety of research platforms, we screen for molecules that selectively target cancer stem cells but spare normal cells. The drugs target key pathways in cancer stem cells and improve survival without signs of toxicity.
CEOCFO: A recent press release mentions your CEP1430 and the CEP1507 compounds. How do they work?
Mr. Sharma: The CEP1430 is a small molecule that selectively targets pancreatic cancer stem cells and significantly inhibits tumor growth rate. CEP1507 has activity against advanced pancreatic cancer that shed circulating tumor cells in the blood stream and contributes to metastatic disease. The CEP1507 targets circulating tumor cells and abrogates metastatic deposits in various organs. The inability to control metastases by various current treatments is a key contributor to patient demise.

CEOCFO: What are your compounds doing that stops the growth?
Mr. Sharma: Celprogen’s compounds halt the growth of cancer stem cells and inhibit metastatic deposits that are eventually responsible for treatment failure and patient death. The cancer stem cells seed the tumor and our compound stops the proliferation and differentiation of cancer stem cells. On the other hand, CEP1507 inhibits circulating tumor cells from embedding into different organs and inhibits key metastatic processes.

CEOCFO: In addition to the research side, are there products and services that you offer as well?
Mr. Sharma: Celprogen offers unique reagents and services in the life sciences area based on our proprietary technology. We provide cancer stem cells isolated from patients and reagents for their routine culture. Reagents include growth media, extracellular matrices pre-coated tissue culture ware that support cancer stem cell research.

CEOCFO: Does that allow you to have funds for the research? Where do the products and services fit into the whole Celprogen picture?
Mr. Sharma: Drug discovery, life science products and services are all part of Celprogen’s growing portfolio.

CEOCFO: How does your approach differ from other researchers? What do you understand at Celprogen that promotes a better result?
Mr. Sharma: Celprogen has collaborated with key industry and academic thought leaders to bring the most current understanding of key biological processes through their proprietary technology in their products and services for the development of efficacious therapeutic candidates for the benefit of cancer patients and research endeavor.

CEOCFO: Is the medical community aware of your approach and research or is it too early for attention?
Mr. Sharma: The medical community is aware of Celprogen’s research, discovery platforms, therapeutic paradigms and products that support cancer research.

CEOCFO: What is the plan for the next year or so?
Mr. Sharma: The plan is to continue with the development of Celprogen’s novel compounds for a quick pathway to clinical translation for the benefit of cancer patients.

CEOCFO: How do you get the attention from the investment community, as there are so many companies in drug development?
Mr. Sharma: Presentation of Celprogen’s novel and unique findings on promising drug candidates for cancer therapeutics are made at research conferences, press releases and publications on Celprogen’s website.
CEOCF0: Why pay attention to Celprogen today?
Mr. Sharma: Celprogen remains dedicated in bringing the most current understanding of biological processes in the tumor microenvironment that support tumor growth and metastases through its unique products and services in translational cancer research for the benefit of patients suffering from this disease.

CEOFO: What might people miss when first looking at Celprogen?
Mr. Sharma: Celprogen is not only a supplier of validated life science products but uniquely positioned through its proprietary technology to bring the most current forms of cancer therapeutics for translational studies in the appropriate clinical setting.

Interview conducted by: Lynn Fosse, Senior Editor, CEOCF0 Magazine